Life Sciences: Biotech
Will Alnylam be the next target for a big tech buyout?
Cambridge drug firm's stock up since Merck deal
It's the classic biotechnology story. One day, you're a Kendall Square start-up with no products and an unproven idea. The next day, one of the world's largest pharmaceutical companies buys your sole competitor for more than $1 billion -- and suddenly everyone is wondering if you're the next big thing. (Full article: 892 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
